-+ 0.00%
-+ 0.00%
-+ 0.00%

Biocon's Pertuzumab Receives Marketing Authorization in EU, First Biosimilar Authorized Under EMA's New Tailored Clinical Approach

Barchart·11/18/2026 07:22:00
Listen to the news

BENGALURU, India, Nov. 18, 2026 /PRNewswire/ -- Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation-led global biopharmaceutical company, today announced that the European Commission (EC) has granted marketing authorization for Pebrilzo®, its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union (EU).

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.